62nd ASH Annual Meeting and Exposition: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III

Oral and Poster Abstracts
Poster

antibodies, Biological, CRS, HSCs, bone marrow, Diseases, Non-Biological, GVHD, Therapies, Adverse Events, Pediatric, Biological Processes, immune cells, Immune Disorders, Technology and Procedures, Cell Lineage, Study Population, Clinically relevant, flow cytometry, immune mechanism, transplantation, inflammation, stem cells, RNA sequencing

3309

Efficacy of Remestemcel-L Treatment in Steroid Refractory Acute Graft-Versus-Host Disease in Children: An Aggregate Analysis

Joanne Kurtzberg, MD¹, Paul J Martin, MD², Susan Prockop, MD³, Elizabeth Burke, ANP⁴^* and Karen Segal, PhD⁵^*

¹Pediatric Stem Cell Transplantation Department, Duke University Medical Center, Durham, NC
²Fred Hutchinson Cancer Research Center, SEATTLE, WA
³Department of Pediatrics, BMT Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Mesoblast, Inc., New York, NY
⁵Mesoblast Inc., New York, NY

3310

Impact of IL-6R Blockade for Cytokine Release Syndrome in Haploidentical Donor Stem Cell Transplant Patients on Infections, Clinical Outcomes and Immune Reconstitution

Katherine P Baker, MD¹^*, Roman M Shapiro, MD², Carol Reynolds, PhD³^*, Benedetta Rambaldi, MD³, Augustine Weber⁴^*, Matilde Dal Boni⁴^*, John Koreth, MBBS, DPhil⁵, Corey Cutler, MD, MPH, FRCPC ⁶, Joseph H. Antin, MD³, Vincent T. Ho, MD²^*, Sarah Nikiforow, MD, PhD⁵, Mahasweta Gooptu, MD³, Catherine J. Wu, MD², Robert J. Soiffer, MD⁷, Jerome Ritz, MD³ and Rizwan Romee, MD⁵

¹Brigham and Women's Hospital, Boston
²Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
³Dana-Farber Cancer Institute, Department of Hematologic Malignancies and Harvard Medical School, Boston, MA
⁴Dana-Farber Cancer Institute, Boston
⁵Dana-Farber Cancer Institute, Boston, MA
⁶Division of Stem Cell Transplantation and Cellular Therapy, Dana-Farber Cancer Inst., Boston, MA
⁷Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

3311

Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for the Assessment of Acute Intestinal GvHD and Prediction of Response to Immunosuppressive Therapy

Georg Evers, MD¹^*, Wolfgang Roll²^*, Jörn Albring¹^*, Christian Reicherts¹^*, Benjamin Noto²^*, Matthias Weckesser²^*, Georg Lenz³, Michael Schäfers²^* and Matthias Stelljes, MD¹

¹Department of Medicine A, University Hospital Muenster, Muenster, Germany
²Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany
³Department of Medicine A, University Hospital Muenster, Munster, Germany

3312

Association of Gene Polymorphisms in Cyclophosphamide Metabolism Pathway with Complications after Haploidentical Hematopoietic Stem Cell Transplantation

Paula Muñiz Sevilla^1,2^*, Cristina Andres^2,3^*, Diego Carbonell, Mr^2,4^*, María Chicano Lavilla, PhD^1,2^*, Rebeca Bailen^1,2^*, Gillen Oarbeascoa⁵^*, Julia Suárez González^2,3^*, Javier Anguita, MD, PhD^1,2^*, Mi Kwon^1,2^*, Jose L. Diez-Martin, MD, PhD^2,4,6, Carolina Martínez-Laperche, PhD^1,2^* and Ismael Buño^1,2,7^*

¹Department of Hematology, Gregorio Marañón General University Hospital, Madrid, Spain
²Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain
³Genomics Unit, Gregorio Marañón General University Hospital (HGUGM), Madrid, Spain
⁴Department of Hematology, Gregorio Marañón General University Hospital (HGUGM), Madrid, Spain
⁵Hematology and Hemotherapy Department, Hospital General Universitario Gregorio M, Madrid, ESP
⁶Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain
⁷Department of Cell Biology, School of Medicine, Complutense University of Madrid, Madrid, Spain

3313

PGE₂ Dependent Inhibition of Macrophage Pyroptosis By MSCs Contributes to Alleviating aGVHD

Xueyan Sun^1,2,3,4^*, Yan Su^1,2,3,4^*, Xiao Liu^1,2,3,4^*, Fengqi Liu^1,2,3,4^*, Gaochao Zhang^1,2,3,4^*, Qi Chen^1,2,3,4^*, Chencong Wang^1,2,3,4^*, Haixia Fu^1,2,3,4^*, Xiaolu Zhu^1,2,3,4^*, Kaiyan Liu^1,2,3,4 and Xiaohui Zhang^1,2,3,4^*

¹National Clinical Research Center for Hematologic Disease, Beijing, China
²Collaborative Innovation Centre of Hematology, Peking University, Beijing, China
³Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
⁴Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China

3314

Comparison of Fixed Vs ALC-Based Doses of Thymoglobulin^® (ATG) in Pediatric Patients with Acute Leukemia Given Αβhaplo-HSCT: Impact on Immune Reconstitution at Day 90

Giulia Barbarito¹^*, David C Shyr, MD¹^*, Gopin Saini, MBBS¹^*, Linda Oppizzi, BS¹^*, Y. Lucy Liu, MD, PhD², Rachana Patil, MS¹^*, Jaap-Jan Boelens, MD, PhD³ and Alice Bertaina, MD, PhD¹

¹Department of Pediatrics/Division of Stem Cell Transplantation and Regenerative Medicine, Stanford School of Medicine, Palo Alto, CA
²Department of Pediatrics/Division of Stem Cell Transplantation and Regenerative Medicine, Stanford Medical School, Stanford, CA
³Memorial Sloan Kettering Cancer Center, New York City, NY

3315

Favorable Immune Reconstitution in Patients Administered Anti-Thymocyte Globulin (ATG) Early in the Course of Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation

Viktoriya Zelikson, BS¹^*, Natasha Raman²^*, Anatevka Rebiero, MD¹^*, Elizabeth Krieger, MD³, Catherine H Roberts, PhD⁴^*, Gary Simmons, DO² and Amir Ahmed Toor, MD⁴^*

¹Virginia Commonwealth University, Richmond, VA
²Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA
³Department of Pediatrics, Virginia Commonwealth University Health System, St Louis Park, MN
⁴Department of Internal Medicine, Virginia Commonwealth University Health System, Richmond, VA

3316

Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic Gvhd Treatment Including Ruxolitinib, Ibrutinib and Imatinib

Swe Mar Linn, MBBS¹, Omar Abduljalil²^*, Igor Nicolas Novitzky-Basso, MD, PhD, MRCP, FRCPath², RAM V Nampoothiri, MD DM MRCP (UK)²^*, Ivan Pasic, MD, PhD²^*, Zeyad Al-Shaibani, MD², Wilson Lam, MD², Arjun Law, MD²^*, Fotios Michelis, MD, PhD²^*, Armin Gerbitz, MD PhD²^*, Auro Viswabandya, MD², Jeffrey H. Lipton, MD, PhD², Rajat Kumar, MD², Jonas Mattson, MD, PhD²^* and Dennis Dong Hwan Kim, MD²

¹Yangon General Hospital, Yangon, Myanmar
²Hans Messner Allogeneic Transplant Program, Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada

3317

Phase 1 Study of Alvelestat, an Oral Neutrophil Elastase Inhibitor, in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation

Annie Im, MD¹, Noa G. Holtzman, MD², Lauren M. Curtis, MD³, Laura Parsons-Wandell, RN⁴^*, Jeannette Nashed, BSN MSN CRNP⁴^*, Cody Peer, PhD⁵^*, William D. Figg, PhD⁶^*, Amisha Barochia, MBBS, MHS⁷^*, Jeremy J. Rose, MS⁸^*, Frances T. Hakim, PhD⁹^* and Steven Z. Pavletic, MD, MS⁴

¹University of Pittsburgh/UPMC Hillman Cancer Center, Pittsburgh, PA
²Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Washington, MD
³Sibley Memorial Hospital, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, Washington, DC
⁴Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
⁵Clinical Pharmacology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
⁶Molecular Pharmacology Section, Genitourinary Malignancies Section, National Cancer Institute, Bethesda, MD
⁷Pulmonary Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD
⁸Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
⁹Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

3318

M1 and M2 Macrophages Play Different Roles in the Pathogenesis of Acute Graft-Versus-Host Disease Post-Allotransplant By Modulating Immune Microenvironment

Qi Wen, MD^1,2^*, Hong-Yan Zhao, PhD¹^*, Zhong-Shi Lyu¹^*, Yao Weili¹^*, Ting-Ting Han¹^*, Yu-Hong Chen¹^*, Yu Wang³^*, Lan-Ping Xu¹^*, Xiao-Hui Zhang¹^*, Yuan Kong¹^* and Xiao-Jun Huang^1,2

¹Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of HSCT, Peking University, Beijing, China
²Nanfang Hospital, Southern Medical University, Guangzhou, China
³Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematology Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China

3319

Long-Term Follow-up of a Randomized Trial of Two Dose Levels of Antithymocyte Globulin in Haploidentical Hematopoietic Stem Cell Transplantation

Yu Wang¹^*, Ren Lin²^*, Lan-Ping Xu³^*, Kai-Yan Liu³, Xiao-Hui Zhang³^*, Qi-Fa Liu²^* and Xiao-Jun Huang^4,5

¹Peking University Institute of Hematology. National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University People’s Hospital, Beijing, China
²Nanfang Hospital, Southern Medical University, Guangzhou, China
³Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease，Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
⁴Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Beijing, China
⁵Peking-Tsinghua Center for Life Sciences, Beijing, China

3320

A Phase 1 Single Dose Escalation Study of Palifermin Administered Pre-Transplant Conditioning in Subjects Undergoing Matched Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation

Alen Ostojic, MD¹, Noa G. Holtzman, MD², Lauren M. Curtis, MD³, Brian C. Shaffer, MD⁴, Jeffrey S Rubin, MD, PhD⁵^*, Frances T. Hakim, PhD⁶^*, Jacqueline W Mays, DDS, PhD⁷^*, Theo Heller, MD⁸^*, Edward W Cowen, MD⁹^*, Sabine Werner, PhD¹⁰^*, Michael Emanuel, BSN, RN¹^*, Seth M. Steinberg, PhD¹¹^*, Ronald E. Gress, MD⁶ and Steven Z. Pavletic, MD, MS¹

¹Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
²Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Washington, MD
³Sibley Memorial Hospital, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, Washington, DC
⁴Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁵NA, Potomac, MD
⁶Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
⁷Oral Immunobiology Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD
⁸Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
⁹Dermatology Branch, National Institute for Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
¹⁰ETH Zurich, Institute of Molecular Health Sciences, Zurich, Switzerland
¹¹Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH